


Current trials
of the North-Eastern German Society of
Gynecological Oncology
(Nord-Ostdeutsche Gesellschaft für Gynäkologische
Onkologie)
www.NOGGO.de



NOGGO Intergroup Study of NOGGO und Studiengruppe Ovar
 (NOGGO-R9, AGO Ovar 2.12)
 AGO-Austria, GEICO

HECTOR Planned Phase-III-Study in platinum-sensitive ovarian cancer patients (status of 9/15/2008: 262 pts)

R A N D O M I S A T I O N		<p>Experimental Arm</p> <table border="0" style="width: 100%; border-collapse: collapse;"> <tr> <td style="padding-right: 20px;">Topotecan</td> <td style="padding-right: 20px;">0.75 mg/m²</td> <td style="padding-right: 20px;">d 1-3</td> <td></td> </tr> <tr> <td>Carboplatin</td> <td>AUC 5</td> <td>d 3</td> <td>q21d</td> </tr> </table>	Topotecan	0.75 mg/m ²	d 1-3		Carboplatin	AUC 5	d 3	q21d							
Topotecan	0.75 mg/m ²	d 1-3															
Carboplatin	AUC 5	d 3	q21d														
	<p>Control arm</p> <table border="0" style="width: 100%; border-collapse: collapse;"> <tr> <td style="padding-right: 20px;">Paclitaxel</td> <td style="padding-right: 20px;">175 mg/m²</td> <td></td> <td></td> </tr> <tr> <td>Carboplatin</td> <td>AUC 5</td> <td></td> <td>q21d</td> </tr> </table> <p>or</p> <table border="0" style="width: 100%; border-collapse: collapse;"> <tr> <td style="padding-right: 20px;">Gemcitabine</td> <td style="padding-right: 20px;">1000 mg/m²</td> <td style="padding-right: 20px;">d 1+8</td> <td></td> </tr> <tr> <td>Carboplatin</td> <td>AUC 4</td> <td></td> <td>q21d</td> </tr> </table>	Paclitaxel	175 mg/m ²			Carboplatin	AUC 5		q21d	Gemcitabine	1000 mg/m ²	d 1+8		Carboplatin	AUC 4		q21d
Paclitaxel	175 mg/m ²																
Carboplatin	AUC 5		q21d														
Gemcitabine	1000 mg/m ²	d 1+8															
Carboplatin	AUC 4		q21d														
	<p>HECTOR Hycamtin <u>at</u> Carboplatin versus Established Regimens for the Treatment of Ovarian Cancer Relapse</p>																

NOGGO-Preference-Trial in Elderly Patients in Recurrent Ovarian Cancer: Treosulfan oral vs. intravenous

Status: 09/15/2008
59pts/100 pts

Randomization

Arm A
Treosulfan
(7000 mg/m²/i.v./d1)
Infusion time: 15-30 min/ q 28d



Arm B
Treosulfan
(600 mg/m²/p.o./d1-28)/28d

NOGGO-Expression II Ovar: What are the expectations and preferences of patients with ovarian cancer on the clinical management and doctor-patients-communication?

(www.expression2.de)



